Scholar Rock announced the appointment of Tracey M. Sacco as Chief Commercial Officer. Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial strategy. At Scholar Rock, she will build and lead all commercial functions, including sales, marketing, market access, and commercial operations.

Her first priority will be preparing the company for the potential commercial launch of apitegromab, the company's Phase 3 investigational candidate for spinal muscular atrophy (SMA). Ms. Sacco joins Scholar Rock with nearly two decades in the biopharmaceutical industry. Much of her career has focused on rare disease, where she has worked on programs from early-stage development through launch.

Most recently, Ms. Sacco worked at The Nemetz Group, where she served as a strategic partner to biopharmaceutical companies on commercialization and corporate strategy. Previously, she held positions of increasing responsibility at Acceleron Pharma, most recently serving as Senior Vice President, Global Strategic Marketing. She was a key architect of the U.S. launch of REBLOZYL for myelodysplastic syndromes and beta-thalassemia.

Prior to Acceleron, Ms. Sacco held roles in commercial strategy and business development at Sanofi (formerly Genzyme), Oscient Pharmaceuticals, and Pfizer. Ms. Sacco holds an M.B.A. from NYU Stern School of Business and a B.A. in Economics and Sociology from Boston College. She is a member of the Life Science Cares Board of Advisors.